Cargando…

Active surveillance for low-risk prostate cancer

Active surveillance for localized prostate cancer entails initial expectant management rather than immediate therapy, with “curative-intent” treatment deferred until there is evidence that the patient is at increased risk for disease progression. This is a response to the clearly documented risks of...

Descripción completa

Detalles Bibliográficos
Autor principal: Klotz, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculty of 1000 Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412317/
https://www.ncbi.nlm.nih.gov/pubmed/22891078
http://dx.doi.org/10.3410/M4-16
_version_ 1782239952287825920
author Klotz, Laurence
author_facet Klotz, Laurence
author_sort Klotz, Laurence
collection PubMed
description Active surveillance for localized prostate cancer entails initial expectant management rather than immediate therapy, with “curative-intent” treatment deferred until there is evidence that the patient is at increased risk for disease progression. This is a response to the clearly documented risks of over diagnosis and overtreatment of low-risk prostate cancer, which in most cases poses little or no threat to the patient. It is based upon the prolonged natural history of prostate cancer and is an attempt to balance the risks and side effects of overtreatment against the possibility of disease progression and a lost opportunity for cure. Low-risk prostate cancer is more accurately viewed as one of multiple risk factors for the presence of higher grade prostate cancer. Like atypical small acinar proliferation, (ASAP), it may be managed with close follow up but without radical intervention, unless there is clear evidence of more aggressive disease.
format Online
Article
Text
id pubmed-3412317
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Faculty of 1000 Ltd
record_format MEDLINE/PubMed
spelling pubmed-34123172012-08-13 Active surveillance for low-risk prostate cancer Klotz, Laurence F1000 Med Rep Review Article Active surveillance for localized prostate cancer entails initial expectant management rather than immediate therapy, with “curative-intent” treatment deferred until there is evidence that the patient is at increased risk for disease progression. This is a response to the clearly documented risks of over diagnosis and overtreatment of low-risk prostate cancer, which in most cases poses little or no threat to the patient. It is based upon the prolonged natural history of prostate cancer and is an attempt to balance the risks and side effects of overtreatment against the possibility of disease progression and a lost opportunity for cure. Low-risk prostate cancer is more accurately viewed as one of multiple risk factors for the presence of higher grade prostate cancer. Like atypical small acinar proliferation, (ASAP), it may be managed with close follow up but without radical intervention, unless there is clear evidence of more aggressive disease. Faculty of 1000 Ltd 2012-08-01 /pmc/articles/PMC3412317/ /pubmed/22891078 http://dx.doi.org/10.3410/M4-16 Text en © 2012 Faculty of 1000 Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes
spellingShingle Review Article
Klotz, Laurence
Active surveillance for low-risk prostate cancer
title Active surveillance for low-risk prostate cancer
title_full Active surveillance for low-risk prostate cancer
title_fullStr Active surveillance for low-risk prostate cancer
title_full_unstemmed Active surveillance for low-risk prostate cancer
title_short Active surveillance for low-risk prostate cancer
title_sort active surveillance for low-risk prostate cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412317/
https://www.ncbi.nlm.nih.gov/pubmed/22891078
http://dx.doi.org/10.3410/M4-16
work_keys_str_mv AT klotzlaurence activesurveillanceforlowriskprostatecancer